Stock SLS SELLAS LIFE SCIENCES GROUP, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials SELLAS Life Sciences Group, Inc.

Equities

SLS

US81642T2096

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
1.45 USD -1.36% Intraday chart for SELLAS Life Sciences Group, Inc. +2.84% +36.79%
May. 19 Certain Common Stock of SELLAS Life Sciences Group, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
May. 14 SELLAS Life Sciences Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 20.95 54.97 87.85 48.59 33.99 84.9 - -
Enterprise Value (EV) 1 20.95 54.97 87.85 48.59 33.99 84.9 84.9 84.9
P/E ratio -0.39 x -2.75 x -4.13 x -1.11 x -0.79 x -2.1 x -2.12 x -2.61 x
Yield - - - - - - - -
Capitalization / Revenue - 28.9 x 11.6 x 48.6 x - - 10.6 x 3.45 x
EV / Revenue - 28.9 x 11.6 x 48.6 x - - 10.6 x 3.45 x
EV / EBITDA - - - - - - - -
EV / FCF - - -3,376,136 x -1,404,975 x - - - -
FCF Yield - - -0% -0% - - - -
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 4,872 9,462 15,886 20,588 32,062 57,755 - -
Reference price 2 4.300 5.810 5.530 2.360 1.060 1.470 1.470 1.470
Announcement Date 3/13/20 3/23/21 3/31/22 3/16/23 3/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - 1.9 7.6 1 - - 7.996 24.64
EBITDA - - - - - - - -
EBIT 1 -17.21 -16.98 -25.29 -41.95 -37.87 -38.67 -37.95 -31.06
Operating Margin - -893.79% -332.82% -4,195% - - -474.66% -126.07%
Earnings before Tax (EBT) 1 -19.37 -16.77 -20.94 -41.3 -37.34 -38.32 -37.76 -30.79
Net income 1 -27.95 -16.84 -20.7 -41.3 -37.34 -38.32 -37.76 -30.79
Net margin - -886.05% -272.36% -4,130.1% - - -472.21% -124.98%
EPS 2 -10.92 -2.110 -1.340 -2.130 -1.340 -0.7000 -0.6933 -0.5633
Free Cash Flow - - -26.02 -34.58 - - - -
FCF margin - - -342.37% -3,458.3% - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 3/13/20 3/23/21 3/31/22 3/16/23 3/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - 1 - - - - - - - - - - -
EBITDA - - - - - - - - - - - - -
EBIT 1 -11.62 -6.735 -8.623 -7.146 -9.446 -11.28 -8.84 -9.361 -8.177 -9.645 -9.594 -9.692 -9.742
Operating Margin - -673.5% - - - - - - - - - - -
Earnings before Tax (EBT) 1 -6.835 -16.74 -8.414 -7.022 -9.121 -11.1 -8.84 -9.267 -8.136 -9.566 -9.512 -9.638 -9.608
Net income 1 -6.598 -16.74 -8.414 -7.022 -9.121 -11.1 -8.84 -9.267 -8.136 -9.566 -9.512 -9.638 -9.608
Net margin - -1,674.4% - - - - - - - - - - -
EPS 2 -0.4200 -1.050 -0.4100 -0.3400 -0.4300 -0.4700 -0.3100 -0.3300 -0.2500 -0.2100 -0.1650 -0.1700 -0.1550
Dividend per Share - - - - - - - - - - - - -
Announcement Date 3/31/22 5/12/22 8/11/22 11/14/22 3/16/23 5/11/23 8/10/23 11/9/23 3/28/24 5/14/24 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - -26 -34.6 - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex - - - - - - - -
Capex / Sales - - - - - - - -
Announcement Date 3/13/20 3/23/21 3/31/22 3/16/23 3/28/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.47 USD
Average target price
5.833 USD
Spread / Average Target
+296.83%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SELLAS LIFE SCIENCES GROUP, INC. Stock SELLAS Life Sciences Group, Inc.
+36.79% 84.9M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.72% 125B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+14.19% 108B
BIONTECH SE Stock BioNTech SE
-4.93% 24.57B
ARGENX SE Stock argenx SE
+3.23% 22.82B
GENMAB A/S Stock Genmab A/S
-10.44% 18.19B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.74% 16.54B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.31% 16.5B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.44% 13.39B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.89% 11.1B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. SLS Stock
  4. Financials SELLAS Life Sciences Group, Inc.